- Home
- VERA vs ZLAB Comparison
VERA vs ZLAB Comparison
Compare VERA & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERA
- ZLAB
- Stock Information
- Founded
- VERA 2016
- ZLAB 2013
- Country
- VERA United States
- ZLAB China
- Employees
- VERA N/A
- ZLAB N/A
- Industry
- VERA Biotechnology: Pharmaceutical Preparations
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- VERA Health Care
- ZLAB Health Care
- Exchange
- VERA Nasdaq
- ZLAB Nasdaq
- Market Cap
- VERA 2.0B
- ZLAB 3.6B
- IPO Year
- VERA 2021
- ZLAB 2017
- Fundamental
- Price
- VERA $23.60
- ZLAB $34.49
- Analyst Decision
- VERA Buy
- ZLAB Buy
- Analyst Count
- VERA 8
- ZLAB 5
- Target Price
- VERA $64.63
- ZLAB $54.28
- AVG Volume (30 Days)
- VERA 1.4M
- ZLAB 782.4K
- Earning Date
- VERA 08-07-2025
- ZLAB 08-05-2025
- Dividend Yield
- VERA N/A
- ZLAB N/A
- EPS Growth
- VERA N/A
- ZLAB N/A
- EPS
- VERA N/A
- ZLAB N/A
- Revenue
- VERA N/A
- ZLAB $418,326,000.00
- Revenue This Year
- VERA N/A
- ZLAB $44.07
- Revenue Next Year
- VERA N/A
- ZLAB $49.13
- P/E Ratio
- VERA N/A
- ZLAB N/A
- Revenue Growth
- VERA N/A
- ZLAB 43.72
- 52 Week Low
- VERA $18.53
- ZLAB $16.01
- 52 Week High
- VERA $51.61
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- VERA 52.93
- ZLAB 45.43
- Support Level
- VERA $22.57
- ZLAB $32.31
- Resistance Level
- VERA $24.58
- ZLAB $35.72
- Average True Range (ATR)
- VERA 1.22
- ZLAB 1.08
- MACD
- VERA 0.14
- ZLAB -0.49
- Stochastic Oscillator
- VERA 69.80
- ZLAB 27.49
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.